1. Toyama H, Li Y, Hatazawa J, Huang G, Kubota K: PET/CT for inflammatory diseases. Basic sciences, typical cases, and review

   • Pasqualina Sannino
   • Luigi Mansi

   Book Review 04 May 2021 Pages: 2665 - 2665

2. A perspective on the EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands

   • Germo Gericke

   Letter to the Editor Open access 13 May 2021 Pages: 2666 - 2667

3. 2021: the year [¹⁷⁷Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?

   • Ken Herrmann
   • Clemens Kratochwil
   • Roland Hustinx

   Editorial Open access 22 May 2021 Pages: 2668 - 2669

4. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavorable intermediate and high-risk prostate cancer

   • John Campaña
   • Patricia Bernal

   Letter to the Editor 04 May 2021 Pages: 2670 - 2671

5. Response to the Letter to the Editor: Prospective comparison of ¹⁸F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer

   • Simona Malaspina
   • Mikael Anttinen
   • Otto Ettala

   Letter to the Editor 14 June 2021 Pages: 2672 - 2673

6. About the source and consequences of ¹⁸F-FDG brain PET hypometabolism in short and long COVID-19

   • Igor C. Fontana
   • Débora Guerini Souza
   • Eduardo R. Zimmer

   Letter to the Editor 04 April 2021 Pages: 2674 - 2675

7. Give to Fryback what is Fryback’s, and to new PET technologies what is new PET technologies’

   • Paulo Schiavom Duarte

   Letter to the Editor 13 June 2021 Pages: 2676 - 2677

8. Women in nuclear medicine

   • Ozgul Ekmekcioglu
   • Laura Evangelista
   • Jolanta Kunikowska

   Editorial 25 May 2021 Pages: 2678 - 2679

9. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy

   • Frederik A. Verburg
   • Julie Nonnekens
   • Marion de Jong

   Editorial 04 January 2021 Pages: 2680 - 2682

10. ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation

    • Sixiang Shi
    • Shreya Goel
    • Weibo Cai

    Editorial 03 May 2021 Pages: 2683 - 2686

11. Molecular imaging with FLT: a case of Cassandra’s curse?

    • Rodney J. Hicks

    Editorial 03 June 2021 Pages: 2687 - 2689

12. Comments to “Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT”

    • Francesco Giammarile
    • Stefano Fanti

    Editorial 19 March 2021 Pages: 2690 - 2691

13. Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article “Survey by the ANSM of the imaging protocol, detection rate, and safety of ⁶⁸Ga-PSMA-11 PET/CT”

    • Yanna-Marina Chevalme
    • Lotfi Boudali
    • Jean-Noël Talbot

    Letter to the Editor Open access 31 May 2021 Pages: 2692 - 2695

14. Moving the goalposts while scoring―the dilemma posed by new PET technologies

    • Julian M.M. Rogasch
    • Ronald Boellaard
    • Carsten Kobe

    Controversies - Against Open access 14 May 2021 Pages: 2696 - 2710

    

15. New PET technologies – embracing progress and pushing the limits

    • Nicolas Aide
    • Charline Lasnon
    • Daniel R McGowan

    Controversies - For Open access 03 June 2021 Pages: 2711 - 2726

    

16. Improved in vivo PET imaging of the adenosine A_2A receptor in the brain using [¹⁸F]FLUDA, a deuterated radiotracer with high metabolic stability

    • Thu Hang Lai
    • Magali Toussaint
    • Peter Brust

    Original Article Open access 02 February 2021 Pages: 2727 - 2736

    

17. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma

    • Miao Li
    • Weijun Wei
    • Weibo Cai

    Original Article 03 February 2021 Pages: 2737 - 2748

    

18. ImmunoPET imaging of multiple myeloma with [⁶⁸Ga]Ga-NOTA-Nb1053

    • Cheng Wang
    • Yumei Chen
    • Weijun Wei

    Original Article 05 February 2021 Pages: 2749 - 2760

    

19. α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [²²³Ra]RaCl₂-treated prostate cancer patients

    • S. Schumann
    • U. Eberlein
    • H. Scherthan

    Original Article Open access 04 February 2021 Pages: 2761 - 2770

    

20. Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure

    • Yan-Ran (Joyce) Wang
    • Lucia Baratto
    • Heike E. Daldrup-Link

    Original Article 01 February 2021 Pages: 2771 - 2781

    

21. Deep learning-based auto-delineation of gross tumour volumes and involved nodes in PET/CT images of head and neck cancer patients

    • Yngve Mardal Moe
    • Aurora Rosvoll Groendahl
    • Cecilia Marie Futsaether

    Original Article Open access 09 February 2021 Pages: 2782 - 2792

    

22. Diagnostic accuracy of stress-only myocardial perfusion SPECT improved by deep learning

    • Hui Liu
    • Jing Wu
    • Yi-Hwa Liu

    Original Article 29 January 2021 Pages: 2793 - 2800

    

23. The EANM practice guidelines for parathyroid imaging

    • Petra Petranović Ovčariček
    • Luca Giovanella
    • Frederik Anton Verburg

    Guidelines Open access 10 April 2021 Pages: 2801 - 2822

24. ¹⁸F-FDG brain PET hypometabolism in patients with long COVID

    • E. Guedj
    • J. Y. Campion
    • C. Eldin

    Original Article 26 January 2021 Pages: 2823 - 2833

    

25. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients

    • Pietro Mattioli
    • Matteo Pardini
    • Dario Arnaldi

    Original Article 28 January 2021 Pages: 2834 - 2845

    

26. A first-in-human study of ¹¹C-MTP38, a novel PET ligand for phosphodiesterase 7

    • Manabu Kubota
    • Chie Seki
    • Makoto Higuchi

    Original Article Open access 10 February 2021 Pages: 2846 - 2855

    

27. Harmonisation of PET/CT contrast recovery performance for brain studies

    • E. E. Verwer
    • S. S. V. Golla
    • R. Boellaard

    Original Article Open access 31 January 2021 Pages: 2856 - 2870

    

28. Prevalence of interstitial pneumonia suggestive of COVID-19 at ¹⁸F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study

    • Domenico Albano
    • Francesco Bertagna
    • On the behalf of Italian Association of Nuclear Medicine (AIMN)

    Original Article Open access 09 February 2021 Pages: 2871 - 2882

    

29. ¹⁸F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study

    • Ryogo Minamimoto
    • Luis Fayad
    • Andrew Quon

    Original Article Open access 28 April 2021 Pages: 2883 - 2893

    

30. Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC

    • Maja Guberina
    • Kaid Darwiche
    • Martin Stuschke

    Original Article Open access 05 February 2021 Pages: 2894 - 2903

31. Use of radiomics based on ¹⁸F-FDG PET/CT and machine learning methods to aid clinical decision-making in the classification of solitary pulmonary lesions: an innovative approach

    • Yi Zhou
    • Xue-lei Ma
    • Rong Tian

    Original Article 05 February 2021 Pages: 2904 - 2913

    

32. Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study

    • Leigh C. Casadaban
    • Paul J. Catalano
    • Paul B. Shyn

    Original Article 09 February 2021 Pages: 2914 - 2924

    

33. Performance of [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients

    • Ali Afshar-Oromieh
    • Marcelo Livorsi da Cunha
    • Isabel Rauscher

    Original Article Open access 04 February 2021 Pages: 2925 - 2934

    

34. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of ⁶⁸Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal ¹⁸F-fluorocholine PET/CT: 1084 examinations

    • Yanna-Marina Chevalme
    • Lotfi Boudali
    • Jean-Noël Talbot

    Original Article Open access 08 January 2021 Pages: 2935 - 2950

    

35. Prospective comparison of ¹⁸F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer

    • Simona Malaspina
    • Mikael Anttinen
    • Otto Ettala

    Original Article Open access 13 March 2021 Pages: 2951 - 2959

    

36. Management impact of ¹⁸F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study

    • Dennie Meijer
    • Pim J. van Leeuwen
    • André N. Vis

    Original Article Open access 05 February 2021 Pages: 2960 - 2969

    

37. Diagnostic value of ¹⁸F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative ⁶⁸Ga-PSMA PET/CT

    • Ruohua Chen
    • Yining Wang
    • Jianjun Liu

    Original Article 02 February 2021 Pages: 2970 - 2977

    

38. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis

    • Ian Leigh Alberts
    • Svenja Elizabeth Seide
    • Ali Afshar-Oromieh

    Original Article Open access 06 February 2021 Pages: 2978 - 2989

    

39. Value of integrated PET-IVIM MRI in predicting lymphovascular space invasion in cervical cancer without lymphatic metastasis

    • Chen Xu
    • Yang Yu
    • Hongzan Sun

    Original Article 27 January 2021 Pages: 2990 - 3000

    

40. Hemichorea induced by non-ketotic hyperglycemia evaluated with ¹⁸F-FDG and ¹¹C-CFT PET/CT

    • Shuilin Zhao
    • Shuang Wu
    • Mei Tian

    Image of the Month 13 February 2021 Pages: 3001 - 3002

    

41. Urachal remnant metastasis detected on [⁶⁸Ga] PSMA-11 PET/CT in an asymptomatic prostate cancer patient with biochemical recurrence

    • Jeeban Paul Das
    • Andreas G Wibmer
    • Heiko Schöder

    Image of the Month 18 February 2021 Pages: 3003 - 3004

    

42. The superiority of [⁶⁸Ga]Ga-FAPI-04 over [¹⁸F]-FDG in a case of neuroendocrine tumour with hepatic metastasis

    • Hao Wang
    • Zunguo Du
    • Wenwei Zhu

    Image of the Month 23 February 2021 Pages: 3005 - 3006

    

43. Pitfalls in PSMA imaging: [¹⁸F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma

    • B. Feuerecker
    • C. Mogler
    • M. Krönke

    Image of the Month Open access 25 February 2021 Pages: 3007 - 3008

    

44. [¹⁸F]FES uptake in the pituitary gland and white matter of the brain

    • R. Iqbal
    • C. W. Menke-van der Houven van Oordt
    • J. Booij

    Image of the Month Open access 17 March 2021 Pages: 3009 - 3010

    

45. [¹⁵³Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma

    • Clemens Kratochwil
    • Frederik L. Giesel
    • Uwe Haberkorn

    Image of the Month Open access 17 March 2021 Pages: 3011 - 3013

    

46. Correction to: Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis

    • Ian Leigh Alberts
    • Svenja Elizabeth Seide
    • Ali Afshar-Oromieh

    Correction Open access 22 March 2021 Pages: 3014 - 3016